I'm cautiously optimistic about the Leronlimab in ARDS. Ideally, we inject patient's that are at high risk of developing ARDS as soon as COVID-19 is diagnosed/suspected in effort to prevent full-blown ARDS. Having treated ARDS patients in the MICU this is a challenging and difficult problem for medical professionals. Worse, when you have more ARDS patients then ventilators, that becomes the ultimate nightmare for a MICU doc. deciding who gets the limited and precious life-saving technology. Here's to hoping for nothing but success for Leronlimab and those patients!